WHO ICTRP trial
A randomized clinical trial for the efficacy and safety of Aliskiren and…
ChiCTR2000032314 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000032314 |
|---|---|
| Public title | A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension |
| Scientific title | A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension |
| Primary sponsor | West China Hospital, Sichuan University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Novel Coronavirus Pneumonia (COVID-19)N; hypertension |
| Interventions | Group 2:Aliskiren with Standard Care;Group 1:Nifedipine with Standard Care |
| Registration date | Apr 25, 2020 |
| Target size | Group 2:121;Group 1:121 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: